Na+/K+ ATPase Inhibitors
1 drugsAbout Na+/K+ ATPase
The Na+/K+ ATPase, or sodium-potassium pump, is an enzyme in the plasma membrane of animal cells. It actively transports sodium ions out and potassium ions into the cell using ATP, establishing electrochemical gradients for nerve impulse transmission and muscle contraction.
The Na+/K+ ATPase is a drug target in the cardiovascular area, as evidenced by the approved drug CARDIOGEN-82. Currently, there is no genetic evidence data available linking variations in the Na+/K+ ATPase gene to specific diseases.
Na+/K+ ATPase is targeted by one FDA-approved drug, CARDIOGEN-82, a small molecule. This drug, developed by BRACCO, was first approved in 1989 for cardiovascular indications.
Top Na+/K+ ATPase Drugs
BRACCO is the only company with an approved drug targeting Na+/K+ ATPase.
The lack of competition suggests a high barrier to entry or an underexplored market.
Na+/K+ ATPase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Na+/K+ ATPase, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
Na+/K+ ATPase Clinical Trials 1 trial
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Na+/K+ ATPase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Na+/K+ ATPase Drug Approval Timeline (1989 - 1989)
The only approved drug, CARDIOGEN-82, was approved in 1989.
The lack of recent approvals indicates a potential for innovation in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 1 (0 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Na+/K+ ATPase. A trial counts if an approved drug acting on Na+/K+ ATPase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.